Dimerix Limited (AU:DXB)
ASX:DXB
Want to see AU:DXB full AI Analyst Report?
DXB Stock Chart & Stats
AU$0.40
-AU$0.03(-5.00%)
At close: 4:00 PM EST
AU$0.40
-AU$0.03(-5.00%)
Day’s Range― - ―
52-Week RangeAU$0.29 - AU$0.79
Previous CloseN/A
Volume4.60M
Average Volume (3M)1.47M
Market Cap
AU$246.16M
Enterprise ValueAU$198.70M
Total Cash (Recent Filing)AU$38.49M
Total Debt (Recent Filing)AU$33.42K
Price to Earnings (P/E)―
Beta2.37
Next Earnings
Sep 02, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.03
Shares Outstanding600,396,800
10 Day Avg. Volume1,720,426
30 Day Avg. Volume1,468,144
Financial Highlights & Ratios
PEG Ratio0.65
Price to Book (P/B)24.09
Price to Sales (P/S)256.86
P/FCF Ratio8.26
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$1.46Price Target Upside265.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.02
Revenue Forecast (FY)AU$18.30M
Bulls Say, Bears Say
Bulls Say
Low LeverageA debt-to-equity ratio of 0.0073 implies minimal interest burden and strong balance sheet conservatism. For a clinical-stage biotech this durable conservatism reduces near-term default risk, preserves optionality to fund trials or wait for higher-value partnerships, and limits fixed financing costs.
Revenue GrowthSustained top-line growth of ~70% demonstrates expanding commercial traction or increasing non-dilutive revenue streams. Over the medium term this growth can validate programs, improve bargaining power in licensing discussions, and support negotiation of milestone-based partnerships.
Cash Flow QualityAn operating cash flow to net income ratio of 1.76 and near-1 free cash flow to net income indicate solid cash conversion versus reported losses. This durable cash quality helps the company fund ongoing R&D and bridge financing needs more predictably between raises or milestone receipts.
Bears Say
Negative ProfitabilityPersistent negative net and EBIT margins show the company is loss-making at an operational level. Over months this necessitates repeated external funding or partnerships, increases dilution risk, and implies the business has not yet achieved scalable cost structures or sustainable margin drivers.
Very Negative ROEA ROE of -99.05% signals severe capital inefficiency and shareholder equity erosion. Structurally this undermines the firm's ability to generate shareholder returns, weakens reinvestment capacity for R&D, and increases the probability of dilutive capital raises or unfavorable deal terms.
Declining Free Cash FlowA steep negative free cash flow growth rate (-307.61%) reflects rapidly worsening cash generation. Over the medium term this raises financing risk, may force hurried equity issuance or low-value partnerships, and can delay critical clinical programs or regulatory milestones.
Dimerix Limited News
DXB FAQ
What was Dimerix Limited’s price range in the past 12 months?
Dimerix Limited lowest share price was AU$0.29 and its highest was AU$0.79 in the past 12 months.
What is Dimerix Limited’s market cap?
Dimerix Limited’s market cap is AU$246.16M.
When is Dimerix Limited’s upcoming earnings report date?
Dimerix Limited’s upcoming earnings report date is Sep 02, 2026 which is in 136 days.
How were Dimerix Limited’s earnings last quarter?
Dimerix Limited released its earnings results on Feb 25, 2026. The company reported -AU$0.027 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.027.
Is Dimerix Limited overvalued?
According to Wall Street analysts Dimerix Limited’s price is currently Undervalued.
Does Dimerix Limited pay dividends?
Dimerix Limited does not currently pay dividends.
What is Dimerix Limited’s EPS estimate?
Dimerix Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Dimerix Limited have?
Dimerix Limited has 600,396,800 shares outstanding.
What happened to Dimerix Limited’s price movement after its last earnings report?
Dimerix Limited reported an EPS of -AU$0.027 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 3.409%.
Which hedge fund is a major shareholder of Dimerix Limited?
Currently, no hedge funds are holding shares in AU:DXB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Dimerix Limited Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
AU$1.46 (265.00% Upside)
AU$1.46 (265.00% Upside)
Blogger Sentiment
Bullish
AU:DXB Sentiment 96%
Sector Average ―
Sector Average ―
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
5.10%
12-Months-Change
Fundamentals
Return on Equity
-83.97%
Trailing 12-Months
Asset Growth
184.23%
Trailing 12-Months
Company Description
Dimerix Limited
Dimerix Limited, a biopharmaceutical company, develops and commercializes pharmaceutical products for unmet medical needs. It develops DMX-200 that is in two Phase 3 clinical trials for COVID respiratory complications; DMX-200, a Phase 3 clinical trial for focal segmental glomerulosclerosis disease; DMX-200 for diabetic kidney disease; and DMX-700 for chronic obstructive pulmonary disease. The company is headquartered in Fitzroy, Australia.
DXB Stock 12 Month Forecast
Average Price Target
AU$1.46
▲(265.00% Upside)
Technical Analysis
Clinuvel Pharmaceuticals
―
Orthocell Ltd
―
Immutep Ltd
―
Race Oncology Ltd.
―
Arovella Therapeutics Limited
―
Options Prices
Currently, No data available
---